BioStock: Alzinova comments on the Letter of Intent in Saudi Arabia
Alzinova recently took a strategic step forward for ALZ-101 by entering a non-binding Letter of Intent with a leading healthcare provider in Saudi Arabia. The deal paves the way for hosting parts of the Phase II trial in the region and exploring joint development and financing for ALZ-101 and ALZ-201. Speaking to BioStock, CEO Tord Labuda explains the background, the shared benefits of the collaboration, and upcoming milestones.
Watch the interview at biostock.se:
Alzinova comments on the letter of intent in Saudi Arabia
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/